PD-L1 is currently the only clinically available and routinely used biomarker for optimizing patient selection for anti-PD-1-ICI in non-small cell lung cancer (NSCLC) (39), gastric cancer and HNSCC (9, 34, 35, 38, 40, 41). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.